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SUMMARY
The present study was designed to examine the potential cellular antiseizure mecha-
nisms of everolimus, a mechanistic target of rapamycin (mTOR) pathway blocker, in
pediatric epilepsy cases. Cortical tissue samples obtained from pediatric patients
(n = 11, ages 0.67–6.75 years) undergoing surgical resections for the treatment of
their pharmacoresistant epilepsy were examined electrophysiologically in ex vivo
slices. The cohort included mTOR-mediated pathologies (tuberous sclerosis complex
[TSC] and severe cortical dysplasia [CD]) as well as non–mTOR-mediated pathologies
(tumor and perinatal infarct). Bath application of everolimus (2 lM) had practically no
effect on spontaneous inhibitory postsynaptic activity. In contrast, long-term applica-
tion of everolimus reduced spontaneous excitatory postsynaptic activity, burst dis-
charges induced by blockade of c-aminobutyric acid A (GABAA) receptors, and
epileptiform activity generated by 4-aminopyridine, a K+ channel blocker. The anti-
seizure effects were more pronounced in TSC and CD cases, whereas in non–mTOR-
mediated pathologies, the effects were subtle at best. These results support further
clinical trials of everolimus in mTOR pathway–mediated pathologies and emphasize
that the effects require sustained exposure over time.
KEYWORDS: Everolimus, Pediatric epilepsy surgery,mTOR pathway, Ex vivo, Mech-
anisms.
Sirolimus, also known as rapamycin, is a naturally occur-
ring molecule first isolated from Streptomyces hygroscopi-
cus on Easter Island in 1964.1 It selectively inhibits the
mechanistic target of rapamycin (mTOR) pathway, which
plays a key role in cell survival, proliferation, metabolism,
and growth.2 Sirolimus has antibiotic, antiproliferative, and
immunosuppressive actions. Everolimus, marketed as Afin-
itor, is a derivative of sirolimus that inhibits the mTOR path-
way via similar mechanisms. Yet, both inhibitors result in
different clinical profiles.3 Everolimus differs structurally
from sirolimus by the addition of a hydroxyethyl ester group
at carbon 40, which is thought to give everolimus its shorter
half-life and greater oral bioavailability.3,4 There also is evi-
dence that, even though both compounds inhibit the mTOR
pathway at comparable doses, only everolimus can dis-
tribute to the mitochondria in the brain.5
Everolimus was first approved by the U.S. Food and Drug
Administration (FDA) in 2009 and is currently used
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primarily to treat breast cancer in postmenopausal women,
to prevent rejection of liver or kidney transplant, and to slow
the growth of certain gastrointestinal and metastatic pancre-
atic neuroendocrine tumors.6,7 In tuberous sclerosis com-
plex (TSC), an autosomal dominant multisystem disorder
that results from mutations in either the TSC1 or TSC2
genes,8 everolimus has been used to reduce the size of
subependymal giant cell astrocytoma (SEGA).9 Clinically,
only everolimus is approved to treat TSC, mainly because
of a lack of phase III studies of sirolimus for TSC, although
several small studies showed sirolimus to be safe and effec-
tive for TSC.3,10 Other clinical trials have been designed to
examine the effects of everolimus on other TSC-related
lesions, such as angiomyolipoma formation in the kidneys
and lymphangioleiomyomatosis.11,12
A hyperactive mTOR pathway plays a key role in the
pathophysiology and seizure development of TSC13 and has
been linked to an increase in a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspar-
tate (NMDA) glutamate receptor expression, and to the
presence of giant cells, reactive astrocytes, and dysplastic
neurons.14,15 Recently everolimus has been shown to have
some antiseizure effects.16 In a prospective, open-label,
phase I/II trial in children with TSC and refractory epi-
lepsy,17 as well as in a double-blind, placebo-controlled and
randomized, global phase III trial in children and adults with
TSC and refractory epilepsy,18 preliminary data showed a
dose-dependent reduction in median seizure frequency with
an acceptable safety profile.18 Although some potential
antiseizure mechanisms of mTOR inhibitors, such as
increased c-aminobutyric acid A (GABAA) receptor–medi-
ated synaptic activity,19 have been gleaned from studies in
TSC animal models, it is not known which mechanisms are
at work in humans and these could be unique due to species
and genetic mutation differences. Using a clinical and basic
research infrastructure at the University of California Los
Angeles (UCLA),20 we set out to study the potential anti-
seizure mechanisms of everolimus in an ex vivo model uti-
lizing freshly excised human cortical tissue from children
with medically refractory focal epilepsy, with or without a




The UCLA Institutional Review Board approved the use
of human subjects for research purposes, and parents or
responsible persons signed informed consents and Health
Insurance Portability and Accountability Act (HIPAA)
authorizations. Because this study was not a clinical trial, it
is not registered in any public registry. Children undergoing
resective surgery with the UCLA Pediatric Epilepsy Pro-
gram to help control their medically refractory focal epi-
lepsy were sequentially recruited between January 2014 and
January 2017. We targeted children ~6 years of age or
younger based on previous studies from our group indicat-
ing that excised cortical tissue samples are in general easier
to process and study than tissue from older patients.21 For
this preliminary study, cortical tissue samples from the fol-
lowing 3 groups of etiologies were included: (1) TSC, with
known mTOR pathway involvement (n = 4); (2) cortical
dysplasia (CD) and hemimegalencephaly (HME) with
implicated PI3K/AKT/mTOR pathway activation22
(n = 4); and (3) non-mTOR pathway etiologies, such as
tumor (n = 1) and perinatal infarct (n = 2).
Electrocorticography and surgical resection
The site and margin of the surgical resection were based
on recommendations from a multidisciplinary meeting after
careful consideration of the presurgical evaluation of each
patient, as reported previously.21 For all 3 groups of etiolo-
gies, we strived for complete resection of the epileptogenic
zone chiefly defined by noninvasive testing20,23,24 including
video–electroencephalography (EEG) capturing ictal
events, high-resolution magnetic resonance imaging (MRI),
and 18-fluorodeoxyglucose–positron emission tomography
(FDG-PET), as well as magnetic source imaging25 and co-
registration of MRI and FDG-PET, as reported previously
when the initial battery of tests was inconclusive.26,27
In the operating room we routinely utilized brief intraop-
erative pre-resection electrocorticography (ECoG) to con-
firm and/or refine the ultimate margins of the surgical
resection. With this brief intraoperative ECoG, high-fre-
quency oscillations, specifically the fast ripple bandwidth
(250–500 Hz), were identified28 in the operating room
before resection began.29 The cortical tissue displaying fast
ripple generation was considered the most epileptogenic
portion of the total resection and was the cortical tissue fur-
ther processed for this study.
Specimen transport, processing, and recording
The fast ripple–generating cortex was resected with no
use of electrocautery. This tissue sample was immediately
immersed in ice-cold artificial cerebrospinal fluid (ACSF)
Key Points
• Everolimus demonstrated antiseizure effects in
mTOR-mediated pathologies; effects in non-mTOR-
mediated pathologies were negligible
• Everolimus antiseizure effects required sustained
exposure over time
• The mechanism whereby everolimus reduces epileptic
activity involves reduction in glutamate receptor–me-
diated excitatory activity
• More extensive clinical studies on the antiseizure
effects of everolimus in mTOR-mediated pathologies
are warranted
Epilepsia Open, 3(s2):180–190, 2018
doi: 10.1002/epi4.12253
181
Antiseizure Effects of Everolimus
enriched with sucrose for better preservation and then expe-
ditiously hand-carried out of the operating room and trans-
ported directly to the laboratory within 5–10 min after
resection. The high sucrose-based slicing solution contained
(in mM): 26 NaHCO3, 1.25 NaH2PO4, 208 sucrose, 10 glu-
cose, 2.5 KCl, 1.3 MgCl2, 8 MgSO4. Coronal slices
(300 lm) were cut and transferred to an incubating chamber
containing ACSF (in mM): 130 NaCl, 3 KCl, 1.25 NaH2PO4,
26 NaHCO3, 2 MgCl2, 2 CaCl2, and 10 glucose oxygenated
with 95% O2-5% CO2 (pH 7.2–7.4, osmolality 290–
310 mOsm/L, 32–34°C). Slices were allowed to recover for
an additional 60 min at room temperature prior to record-
ing. All recordings were performed at room temperature
using an upright microscope (Olympus BX51WI) equipped
with infrared-differential interference contrast (IR-DIC)
optics.
Whole-cell patch-clamp recordings in voltage- or cur-
rent-clamp modes were obtained from cortical pyramidal
neurons (layers II–V) visualized with IR-DIC.30 The patch
pipette (3–5 MΩ resistance) contained a cesium-based
internal solution (in mM): 125 Cs-methanesulfonate, 4 NaCl,
1 MgCl2, 5 MgATP, 9 ethylene glycol-bis(-aminoethyl
ether)-N,N,N',N'-tetraacetic acid (EGTA), 8 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 Gua-
nosine-50-triphosphate (GTP)-Tris, 10 phosphocreatine, and
0.1 leupeptin (pH 7.2 with CsOH, 270–280 mOsm/L) for
voltage clamp recordings. K-gluconate–based solution con-
taining (in mM): 112.5 K-gluconate, 4 NaCl, 17.5 KCl, 0.5
CaCl2, 1 MgCl2, 5 ATP, 1 NaGTP, 5 EGTA, 10 HEPES, pH
7.2 (270–280 mOsm/L) was used for current clamp record-
ings. After breaking through the membrane, cell properties
(capacitance, input resistance, and decay time constant)
were recorded while the membrane potential was held at
70 mV. Electrode access resistances during whole-cell
recordings were <25 MΩ.
After characterizing membrane properties, neuronal
excitability was determined in current clamp mode before
and after addition of everolimus (Tocris, 200 nM and 2 lM
in 0.1% Dimethyl sulfoxide). In voltage clamp, spontaneous
excitatory and inhibitory postsynaptic currents (sEPSCs and
sIPSCs) were measured to determine changes after bath
application of everolimus. Amplitude, frequency, and kinet-
ics of spontaneous synaptic currents were assessed using
MiniAnalysis software. Because spontaneous epileptic
activity does not occur frequently in slices, cellular hyperex-
citability was induced by bath application of proconvulsant
agents such as K+ channel blocker 4-aminopyridine (4-AP,
100 lM) and/or the GABAA receptor antagonist bicuculline
(BIC, 20 lM).31 In this exploratory study, different experi-
mental conditions were used to maximize data collection. In
most cases, the effects of everolimus on membrane oscilla-
tions induced by 4-AP were examined in voltage clamp
mode (+10 or 70 mV holding potential). After a stable
baseline of epileptiform discharges was obtained (usually
within 5–7 min) everolimus was applied either acutely (10–
15 min) or for longer periods (>15 min). In a few cases,
slices were pre-incubated for 1–2 h in everolimus. The
effects of everolimus on 4-AP membrane oscillations were
then correlated with the 3 groups of etiologies mentioned
earlier, namely TSC, CD etiologies with mTOR involve-
ment, and non-mTOR etiologies.
Statistics
In the text and figures, results are expressed as mean  s-
tandard error of the mean (SEM). For group comparisons,
we used one-way analysis of variance (ANOVA; with Bon-
ferroni correction) or ANOVA of Ranks (Dunn’s method)
tests. To evaluate the effects of everolimus, a paired Stu-
dent’s t-test or a chi-square test was used. Statistical signifi-
cance was set at p < 0.05.
Results
Cohort and number of cells recorded
Eleven patients were recruited for the 3 types of etiolo-
gies: 4 children with TSC, 4 children with CD/HME, and 3
children with non-mTOR etiologies (one postresection for
tumor and 2 perinatal infarct cases). The CD cases included
CD type Ic (n = 2), CD type IIa/HME (n = 1), and CD type
IIb (n = 1), as defined by the International League Against
Epilepsy (ILAE) classification of CDs.32 In the present
cohort, 2 of the patients were female (both with non-mTOR
pathologies). There was a statistically significant interaction
in mean age values among groups (p = 0.044, one-way
ANOVA), with the non-mTOR group (5.4  1 year) being
older than the CD/HME (2.5  0.8 year) and TSC
(2.1  0.4 year), consistent with our previous studies.20
However, post hoc (Bonferroni t-test) comparisons between
groups did not yield significant differences. If non-mTOR
cases (5.4  1 year, n = 3) were compared with cases
involving mTOR activation (CD + TSC, 2.3  0.5 year,
n = 8), the age difference became statistically significant
(p = 0.01, Student’s t-test). The clinical findings of these 11
children are detailed in Table 1.
Each cortical resection had between 2 and 6 individual
neurons studied, with and without everolimus. In total, 66
neurons were recorded, and of those 45 were tested for
everolimus and/or pro-convulsant drugs under different
experimental conditions (TSC cases n = 18 cells, CD/
HME cases n = 12 cells, and non-mTOR cases n = 15
cells). Of those, 42 were tested with everolimus and 3
were only tested with 4-AP for comparison. Recorded
cells were pyramidal neurons that included a majority of
normal-appearing pyramidal neurons (n = 39), immature
(n = 1 from a TSC case), and dysmorphic cytomegalic
pyramidal neurons (n = 5, 4 from 2 TSC cases and 1 from
a CD type IIa/HEM case), as defined by the ILAE classi-
fication of CD32. Balloon cells were seen occasionally but
were not tested with everolimus. Regardless of treatment,
cells were filled with biocytin during recordings and then
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processed histologically. Some typical examples of pyra-
midal neurons recorded in this cohort are shown in Fig-
ure 1A.
Biophysical membrane properties
Basic membrane properties (cell capacitance, input
resistance, and decay time constant) were calculated in
voltage clamp mode by applying a 10 mV depolarizing
voltage command from a holding voltage (Vh) of
70 mV and using the pClamp software. There was a sta-
tistically significant difference in cell membrane capaci-
tance among groups (p = 0.039, one-way ANOVA on
ranks). The average cell capacitance was larger in TSC
compared with CD and non-mTOR groups. This probably
reflects the fact that in TSC cases some pyramidal neu-
rons are larger as a result of mTOR pathway activation.
In contrast, we observed a strong, albeit nonsignificant
trend (p = 0.079), for membrane input resistance to be
decreased in neurons from TSC cases, in general agree-
ment with the observation that these cells were larger.
The decay time constant was not significantly different
among neurons from the 3 groups (Fig. 1B).
Effects of everolimus on spontaneous synaptic activity
A potential mechanism of antiepileptic effects for any
given drug is re-establishment of the synaptic excitatory/in-
hibitory balance. For example, everolimus could exert
antiepileptic effects by increasing GABAergic activity.
Thus, we tested the effects of everolimus on sIPSC fre-
quency by holding the membrane at +10 mV. At this poten-
tial, synaptic currents are mediated by GABAA receptors.
31
In 5 neurons examined, bath application of everolimus pro-
duced inconsistent effects, with some cells showing small
increases (n = 2) and other cells showing small decreases
(n = 3) (Fig. S1). On average, the frequency was reduced
by about 10%, suggesting that everolimus does not affect
GABAergic neurotransmission onto pyramidal neurons in a
significant way. Furthermore, kinetic analysis of sIPSCs
revealed no changes in rise or decay times (Table 2 and
Fig. S2).
Antiepileptic effects may also occur via reduction of
excitatory inputs. To test this possibility, we bath applied
everolimus after recording baseline spontaneous synaptic
activity (2–3 min) at a holding potential of70 mV. At this
potential, synaptic activity is mediated primarily by gluta-
mate AMPA receptors. To fully isolate glutamatergic
synaptic currents, the GABAA receptor antagonist BIC
(20 lM) was added to the external solution. Long-term
(>15 min) application of everolimus (n = 8 cells from 2
TSC cases and one stroke case) produced a significant
reduction in the frequency of sEPSCs (Fig. 2A,B). Further-
more, synaptic bursts and large-amplitude events commonly
observed after BIC application also were reduced. The aver-
age percent reduction in frequency after everolimus was
35%. The most dramatic effects were seen in one cell (TSC,
1.16-year-old) that had been incubated in everolimus for
>1 h. In this case, the frequency in 2 cells that received no
treatment was 4.1  1.1 Hz, whereas in the cell incubated
in everolimus, the sEPSC frequency was 0.8 Hz. Kinetic
analysis of sEPSCs revealed no changes in rise or decay
times (Table 2 and Fig. S2). This suggested that one possi-
ble mechanism of antiepileptic activity is via reduction of
glutamate AMPA receptor–mediated synaptic activity.
Effects of everolimus on pharmacologically induced
paroxysmal activity
Spontaneous epileptiform activity rarely occurs in
ex vivo conditions even when the sample is from the epilep-
togenic zone. This is probably because of interruption of
long-range excitatory circuits caused by the slicing proce-
dure. Epileptiform activity in cortical tissue can be induced
by 4-AP (a compound that blocks the A-type K+ current,
thereby facilitating neurotransmitter release) and/or by
blocking inhibitory transmission with the GABAA receptor
antagonist BIC.
Within 2–4 min after bath application of 4-AP (100 lM,
with or without BIC), spontaneous rhythmic epileptiform
Table 1. Cohort characteristics
Pt no. Pathology Age at surgery (year) Gender No. AEDs at surgery Area of resection Area of FR studied
1 CD type IIa/HEM 0.67 M 2 LH LFP
2 CD type Ic/Heterotopia 1.50 M 2 RH RTP
3 CD type Ic 2.33 M 4 LH LFT
4 CD type IIb 2.33 M 2 LTP LP
5 TSC 1.16 M 3 LF LF
6 TSC 2.16 M 4 RF RF
7 TSC 2.45 M 3 LF LF
8 TSC 2.75 M 3 RF RF
9 Teratoma 3.58 F 1 RH RF
10 Perinatal infarct 5.82 M 2 LH LF
11 Perinatal infarct 6.75 F 3 RH RTP
AED, antiepileptic drug; FR, fast ripples; TSC, tuberous sclerosis complex; M, male; F, female; L, left; R, right; H, hemisphere; F, frontal; T, temporal; P, parietal.
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discharges occurred in most pyramidal neurons. The fre-
quency of these membrane oscillations remained relatively
constant, but the amplitude tended to decrease progres-
sively. The average frequency of 4-AP oscillations was 9.4/
min (n = 16 cells), with no difference among groups (TSC,
7.8  2/min, CD 10  4/min and non-mTOR 9.9  1/
min, p = 0.79). Initial pilot studies tested 2 doses of everoli-
mus: 200 nM and 2 lM. However, it soon became evident
Figure 1.
A, Examples of pyramidal-shaped neurons that were recorded electrophysiologically, tested for everolimus, and filled with biocytin to
examine morphology. Notice that these cells displayed signs of atrophy including sparse dendritic spines and blebbing. Calibration in the
middle panel applies to all. B, Basic membrane properties in the 3 groups. Cell capacitance was significantly different among groups, with
cells from TSC cases being larger than those from non-mTOR and CD cases. There was a trend for input resistance to be different among
groups. Decay time constant was not significantly different among groups (p = 0.31).
Epilepsia Open ILAE
Table 2. (A) sEPSC kinetics and (B) sIPSC kinetics
Rise time (msec) Half-amplitude duration (msec) Decay time (msec) Area (pA/msec) Amplitude (pA)
(A)
Control 0.9  0.1 6.0  0.4 6.0  0.6 106.3  8.7 7.7  0.6
Everolimus 0.9  0.1 5.3  0.2 5.0  0.4 112.1  10.3 7.6  0.6
(B)
Control 3.5  0.6 25.6  4.4 32.3  6.3 952.1  134.2 22.7  1.0
Everolimus 3.3  0.5 28.1  4.8 39.4  6.8 1,032  195.7 22.7  2.3
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that the lower dose produced no detectable effects (n = 3
cells from 2 TSC cases) (not shown). The effects of everoli-
mus (2 lM) on 4-AP oscillations were tested in 3 conditions:
(1) simultaneous application of everolimus and 4-AP; (2)
everolimus added soon after induction of steady 4-AP oscil-
lations (about 4–5 min after drug application) and kept in
the bath for more than 15 min; and (3) after long-term pre-
incubation (1–2 h) of the slices in everolimus. Simultaneous
application of 4-AP, BIC, and everolimus did not affect the
frequency of epileptiform discharges (n = 2) (not shown).
Most cells were tested with acute, prolonged application of
the drug in the bath solution.
In cells from TSC cases, everolimus demonstrated
antiepileptic effects in 8 cells and no clear effects in one
cell. This effect was manifested by a reduction in the fre-
quency and/or amplitude of 4-AP oscillations (Fig. 3A and
Fig. S3). Remarkably, incubation in everolimus for 1–2 h
fully prevented the occurrence of epileptiform activity
(Fig. 3B). Only an increase in the frequency and amplitude
of spontaneous synaptic events occurred. In CD/HME
cases, everolimus also displayed antiepileptic effects. Ever-
olimus reduced the frequency of 4-AP-induced paroxysmal
discharges in 4 cells (Fig. 4A) and had no effect in 2 cells.
In current clamp mode, epileptiform activity induced by
BIC and 4-AP led to membrane oscillations and burst firing
at depolarized potentials. After everolimus, membrane
oscillations subsided and the firing pattern became regular
instead of bursting (Fig. 4B). Finally, in pyramidal neurons
from non-mTOR pathologies, the effects of everolimus
were subtle at best (n = 3), and in most cases no effects
were observed (n = 4), even after long-term incubation in
the drug (Fig. 5). There was a statistically significant differ-
ence in everolimus effects between the TSC and the non-
mTOR group (p = 0.049, chi-square test, n = 9 and 7 cells,
respectively), whereas the difference between mTOR (TSC
and CD combined) and non-mTOR pathologies almost
reached statistical significance (p = 0.08, chi-square test).
On average, in mTOR pathologies everolimus reduced the
frequency of membrane oscillations from 7.7  2/min to
5.7  2/min (p = 0.002, paired t-test). In non-mTOR
pathologies, the effect was subtle and not statistically signif-
icant. On average, the frequency of membrane oscillations
changed from 7.3  0.5/min to 6.3  1/min (p = 0.423,
paired t-test).
Discussion
Significant advances have been made in recent years
toward understanding the mechanism of action of everoli-
mus. Yet, the details of its antiseizure properties remain to
be elucidated. In this study, comparing ex vivo brain slices
from TSC, CD/HME, and non-mTOR pathologies, we
demonstrate that everolimus had clear and robust anti-sei-
zure effects in the TSC and CD/HME groups. In the non–
mTOR-mediated posttumor and postinfarct etiologies the
effects of everolimus were mild or nonexistent. These find-
ings are similar to those of previous reports from our labora-
tory showing antiseizure effects of rapamycin in TSC and
CD cases but not in non-CD pathologies.33,34 The results
from these studies further validate the potential antiseizure
effects of rapamycin and everolimus in pathologies involv-
ing hyperactivation of the mTOR pathway.
Because this study selected the most epileptogenic corti-
cal tissue with ECoG, specifically with high-frequency
oscillations, the removal of which has been highly associ-
ated with postoperative seizure freedom,28,29 the results
would likely closely resemble the antiseizure effects of
mTOR inhibitors in a clinical scenario. These findings are
Figure 2.
A, Example traces showing the effects of everolimus on the frequency of sEPSCs recorded from 2 TSC cases. Cells were held at70 mV
to minimize the contribution of inhibitory synaptic activity and BIC (20 lM) was added to the ACSF. Long-term (>15 min) application of
everolimus reduced the frequency of sEPSCs and also decreased bursting activity (arrow), as well as the occurrence of large-amplitude
synaptic events. B, The bar graph indicates there was a statistically significant change in sEPSC frequency after everolimus (p = 0.01,
paired t-test, n = 8 cells).
Epilepsia Open ILAE
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encouraging for a pilot clinical trial in children with CD or
HME, and medically refractory epilepsy, to test the efficacy
and safety of everolimus in these 2 mTOR-mediated condi-
tions.
It is interesting to note that only the higher everolimus
concentration demonstrated antiseizure effects, whereas
the lower everolimus concentration did not. This observa-
tion is consistent with the better efficacy found with the
higher everolimus arm of the EXamining everolimus In a
Study of Tuberous sclerosis complex (EXIST-3) epilepsy
trial in TSC.18 This higher dose was better tolerated in
children 6 years of age and younger,18 which notably is
the same age group as in this ex vivo study. The signifi-
cantly younger age of the TSC and CD/HME groups at
the time of surgery, compared with the non-mTOR group,
reflects the highly epileptogenic and medically refractory
Figure 3.
A, Epileptiform activity was induced by bath application of 4-AP and BIC in a pyramidal neuron from a TSC case. The cell was held at
70 mV. Addition of everolimus reduced the amplitude and frequency of epileptiform activity. This effect partially washed out after
removal of everolimus. B, The most dramatic effects were observed with pre-incubation of slices in everolimus. Top trace shows the
effect of 4-AP application in a cell from a slice incubated in ACSF only (TSC case). Oscillations and paroxysmal discharges were induced.
In a slice incubated for 2 h in everolimus, the effects of 4-AP were significantly reduced and no paroxysmal discharges were observed.
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nature of these mTOR-mediated conditions. Indeed, corti-
cal malformations constitute the most prevalent pathologic
diagnosis for children undergoing epilepsy surgery, com-
prising 25–40% of the refractory childhood epilepsies.35
Approximately 75% of patients with cortical malforma-
tions will have epilepsy at some point in their lifetime.36
Cell membrane properties were different among patholo-
gies. TSC cells were larger than in other pathologies. This
was expected due to mTOR activation. Although a few
cytomegalic neurons were observed in CD cases, the aver-
age size was not increased, probably because the CD group
included CD type I and type II/HME cases. In addition to
the pathology, time of exposure to the drug determined the
intensity of the effect. When applied simultaneously with 4-
AP, everolimus had no effect. When applied acutely but for
a long time, a decrease in epileptiform activity was
observed. However, everolimus was most effective after
long-time (1–2 h) incubation. Under these conditions, the
latency to paroxysmal events was delayed and their fre-
quency and amplitude were drastically reduced. Similarly,
everolimus reduced the frequency of sEPSCs with long-
term application.
To date, it is still unclear how everolimus has antiseizure
properties in TSC because it is also unclear how exactly
tubers contribute to seizure activity. Cortical tubers have
been shown to have decreased GABAA receptor levels and
possess cytomegalic cells that may indicate altered matura-
tion and enhanced excitability.30,37,38 It also has been shown
Figure 4.
A, In CD cases, similar to the effects observed in TSC cases, everolimus reduced the frequency of 4-AP membrane oscillations. B, Effects
of everolimus on action potential firing induced by depolarizing current (+170 pA). In control conditions (ACSF), regular firing was
evoked by current injection. After addition of BIC and 4-AP, membrane oscillations and burst firing occurred. Everolimus reduced mem-
brane oscillations and bursting activity.
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that neurons in the immediate area of the tubers have
increased excitability.39,40 The timing of everolimus admin-
istration in the course of the disease seems relevant to its
effect, suggesting that its role in inhibiting the mTOR path-
way may alter the aberrant growth of neurons and contribute
to its therapeutic effect.33
With regard to the possible mechanism(s) by which ever-
olimus produces antiepileptic effects and based on the fact
that long-term exposure to the drug reduced the frequency
of sEPSCs, we could speculate that one potential mecha-
nism could involve a decrease in cell membrane surface
expression of glutamate AMPA receptors. Indeed, in cell
models it has been shown that the mTOR pathway regulates
the surface expression of AMPA receptors41 and in animal
models rapamycin decreases glutamatergic synaptic trans-
mission.42 Thus, long-term exposure to everolimus, at least
in cortical pyramidal neurons, could internalize AMPA
receptors, thereby decreasing glutamate-induced membrane
depolarization. We also found that in current clamp mode,
everolimus changed the firing pattern from bursting to con-
tinuous firing, suggesting that bursting activity and syn-
chrony are disrupted by drug application. Another potential
mechanism involves direct effects of mTOR inhibitors on
astrocytes and GLT-1 glutamate transporter expression. For
example, recent evidence indicates that rapamycin can
upregulate GLT-1 expression.43–46
Significance and Limitations
The present study has a number of limitations inherent to
the use of human pathologic brain tissue. First, all patients
were taking antiseizure medication and this may have
affected the different outcomes. Second, the use of an
ex vivo model, which is a reduced preparation,47 does not
allow examination of the role of long-range projections.
Third, due to the scarcity of pediatric epilepsy surgical
tissue, a more-detailed quantitative analysis was not feasi-
ble. By design, this was primarily an exploratory study on
everolimus antiseizure effects. Thus, we had to rely on con-
vergent evidence from different experimental conditions to
provide a glimpse into drug mechanisms and draw some
tentative conclusions. Finally, we only examined everoli-
mus effects on neuronal cells and we know that mTOR-
mediated abnormalities, including epileptogenesis, are not
only restricted to neurons but also to non-neuronal popula-
tions. For example, mouse models of TSC can display sei-
zures when the Tsc1 gene is removed from glial cells
only.48,49 Thus, future work should also study the effects of
everolimus on non-neuronal populations. Despite these lim-
itations, studying the electrophysiologic effects of everoli-
mus in human tissue from patients with epilepsy represents
a good model that closely resembles physiologic conditions
in a controlled environment. The present results shed some
light on cellular mechanisms of drug actions and support the
need for additional studies, in particular examination of sur-
face expression of AMPA receptors before and after everoli-
mus treatment, as well as its effect on glutamate
transporters.
Acknowledgments
This study was supported by an investigator-initiated study between
JYW and Novartis Pharmaceutical Inc. (study number RAD001-
MUS246T). GWM was supported by the Davies/Crandall Endowed Chair
for epilepsy research at UCLA. We would like to thank the patients and
their parents for allowing the use of resected specimens for experimenta-
tion. We also thank the UCLA Hospital Pediatric Neurology staff for their
assistance. Ms. My N. Huynh did the biocytin processing.
Disclosure
None of the authors has any conflict of interest to disclose. We confirm
that we have read the Journal’s position on issues involved in ethical publi-
cation and affirm that this report is consistent with those guidelines.
Figure 5.
Effects of everolimus in a non-mTOR case (tumor). In a cell recorded in a slice that received no treatment, 4-AP rapidly induced mem-
brane oscillations. In the cell recorded in a slice incubated for 1 h in everolimus, besides an increase in latency and slightly lower frequency
of membrane oscillations, the effects were only mild compared with those observed in mTOR cases.
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Figure S1. Example traces showing the effects of everoli-
mus on the frequency of sIPSCs. Cells were held at +10 mV
to minimize the contribution of excitatory synaptic activity.
Acute bath application of everolimus (2 lM for about
15 min) did not affect IPSC frequency significantly. On
average, there was only a small, nonsignificant decrease.
Figure S2. Everolimus did not affect sEPSC or sIPSC
kinetics. Traces are averages of total spontaneous synaptic
events recorded in one cell. Average values are shown in
Table 2.
Figure S3. Top trace shows the effect of 4-AP application
in a cell from a slice incubated in ACSF only. Oscillations
and paroxysmal discharges accompanied by large inward
currents were induced. In a slice incubated for 70 min in
everolimus, 4-AP oscillations were significantly reduced
and no paroxysmal discharges were observed.
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